SYK and breast cancer: This is in contradiction to the findings of Blancato et al. [12] who reported that SYK deletion was highly prevalent in infiltrating breast cancers, although it should be noted that these conclusions were a result of the analysis of only 11 infiltrating breast cancer samples and 8 non-infiltrating breast cancer samples, and that SYK loss was observed in just 5 of the 11 infiltrating tumours and none of the 8 non-infiltrating tumours.